Đánh giá kết quả điều trị của Tocilizumab (Actemra) ở bệnh nhân viêm khớp dạng thấp

This study was carried out to determine the Tocilizumab (Artemra) efficacy and safely in rheumatoid arthritis after 12 weeks treated. The result showed that there was improvement of both clinical and disease activity such as VAS (from 7.7 to 1.9), DAS28-CRP (from 5.45 to 2.1) others inflammation indeck (ESR, CRP) were significantly reduced with (p 0.01). No side effects of drug was recognized. In conclusion, Tocilizumab (Artemra) has efficacy in rheumatoid arthritis treatment.